JP2006528166A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528166A5
JP2006528166A5 JP2006520908A JP2006520908A JP2006528166A5 JP 2006528166 A5 JP2006528166 A5 JP 2006528166A5 JP 2006520908 A JP2006520908 A JP 2006520908A JP 2006520908 A JP2006520908 A JP 2006520908A JP 2006528166 A5 JP2006528166 A5 JP 2006528166A5
Authority
JP
Japan
Prior art keywords
bacteriophages
bacteriophage
ncimb
use according
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006520908A
Other languages
Japanese (ja)
Other versions
JP2006528166A (en
JP5731727B2 (en
Filing date
Publication date
Priority claimed from GB0317240A external-priority patent/GB0317240D0/en
Priority claimed from GB0410855A external-priority patent/GB0410855D0/en
Application filed filed Critical
Priority claimed from PCT/GB2004/003237 external-priority patent/WO2005009451A1/en
Publication of JP2006528166A publication Critical patent/JP2006528166A/en
Publication of JP2006528166A5 publication Critical patent/JP2006528166A5/ja
Application granted granted Critical
Publication of JP5731727B2 publication Critical patent/JP5731727B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Claims (32)

生物膜形成を特徴とする細菌感染症を処置する目的で、（ｉ）１若しくはそれ以上のバクテリオファージ、及び（ｉｉ）１若しくはそれ以上の抗生物質、を同時、別個、又は連続投与するための複合製品の製造における、（ｉ）及び（ｉｉ）の使用。   For the simultaneous, separate or sequential administration of (i) one or more bacteriophages and (ii) one or more antibiotics for the purpose of treating a bacterial infection characterized by biofilm formation Use of (i) and (ii) in the manufacture of composite products. 単一の複合バクテリオファージ調製物の製造において２以上のバクテリオファージを用いる、請求項１記載の使用。   Use according to claim 1, wherein two or more bacteriophages are used in the production of a single complex bacteriophage preparation. 前記複合バクテリオファージ調製物が、同じ細菌種に感染しうる複数種のバクテリオファージを含み、該複数種のバクテリオファージの各メンバーがそれぞれ異なる株特異性を有する、請求項２記載の使用。   The use according to claim 2, wherein the complex bacteriophage preparation comprises a plurality of bacteriophages capable of infecting the same bacterial species, each member of the plurality of bacteriophages having a different strain specificity. １若しくはそれ以上の抗生物質が、１若しくはそれ以上のバクテリオファージより後に投与される、請求項１〜３のいずれか１項に記載の使用。   4. Use according to any one of claims 1 to 3, wherein the one or more antibiotics are administered after the one or more bacteriophages. 前記細菌感染症が緑膿菌（Pseudomonas aeruginosa）を含むか又はそれからなる、請求項１〜４のいずれか１項に記載の使用。   Use according to any one of claims 1 to 4, wherein the bacterial infection comprises or consists of Pseudomonas aeruginosa. 前記感染症が、皮膚熱傷部若しくは他の皮膚創傷部の感染症、肺感染症、眼感染症又は耳感染症から選択される感染症である、請求項５記載の使用。   6. Use according to claim 5, wherein the infection is an infection selected from infections of skin burns or other skin wounds, lung infections, eye infections or ear infections. 前記感染症がイヌの耳感染症である、請求項６記載の使用。   7. Use according to claim 6, wherein the infection is a dog ear infection. 前記投与が予防的処置のためのものである、請求項１〜５のいずれか１項に記載の使用。   6. Use according to any one of claims 1 to 5, wherein the administration is for prophylactic treatment. 前記複合製品が、コンタクトレンズ用溶液又は添加剤である、請求項８記載の使用。   Use according to claim 8, wherein the composite product is a contact lens solution or additive. ＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８、ＮＣＩＭＢ４１１７９、ＮＣＩＭＢ４１１８０及びＮＣＩＭＢ４１１８１（National Collection of Industrial and Marine Bacteria、Aberdeen、英国、に寄託されている）、並びに緑膿菌（P. aeruginosa）を標的とする能力を保持するこれらの変異株から選択される１若しくはそれ以上のバクテリオファージを用いる、請求項５〜９のいずれか１項に記載の使用。   NCIMB41174, NCIMB41175, NCIMB41176, NCIMB41177, NCIMB41178, NCIMB41179, NCIMB41180 and NCIMB41181 (deposited in the National Collection of Industrial and Marine Bacteria, Aberdeen, UK), and P. aeruginosa targeting Use according to any one of claims 5 to 9, wherein one or more bacteriophages selected from these mutant strains to be retained are used. バクテリオファージの集団が用いられ、該集団の各メンバーは、それぞれ異なる株特異性を有し、且つＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８及びＮＣＩＭＢ４１１７９、ＮＣＩＭＢ４１１８０及びＮＣＩＭＢ４１１８１、並びに緑膿菌（P. aeruginosa）を標的とする能力を保持するこれらの変異株から選択される、請求項１０記載の使用。   A population of bacteriophages is used, each member of which has a different strain specificity and is NCIMB 41174, NCIMB 41175, NCIMB 41176, NCIMB 41177, NCIMB 41178 and NCIMB 41179, NCIMB 41180 and NCIMB 41181, and P. aeruginosa 11. Use according to claim 10, selected from these mutants which retain the ability to target 用いられるバクテリオファージの集団が、ＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８、ＮＣＩＭＢ４１１７９よりなるか、又は前記のバクテリオファージのいずれかが所望の標的株特異性を示すその変異株に置換されている点で前記集団とは異なる集団である、請求項１１記載の使用。   In that the bacteriophage population used consists of NCIMB 41174, NCIMB 41175, NCIMB 41176, NCIMB 41177, NCIMB 41178, NCIMB 41179, or any of the bacteriophages has been replaced by a variant thereof exhibiting the desired target strain specificity. 12. Use according to claim 11, wherein the population is different from the population. 前記バクテリオファージの集団が、イヌの耳感染症の処置での使用ための単一の複合バクテリオファージ調製物の製造において用いられる、請求項１２記載の使用。   13. Use according to claim 12, wherein the bacteriophage population is used in the manufacture of a single composite bacteriophage preparation for use in the treatment of canine ear infections. １若しくはそれ以上のバクテリオファージと、同時、別個又は連続投与するためのアルギナーゼの使用をさらに含む、請求項１〜１３のいずれか１項に記載の使用。   14. Use according to any one of claims 1 to 13, further comprising the use of arginase for simultaneous, separate or sequential administration with one or more bacteriophages. National Collection of Industrial and Marine Bacteria、Aberdeen、英国、に寄託されているバクテリオファージ株ＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８、ＮＣＩＭＢ４１１７９、ＮＣＩＭＢ４１１８０及びＮＣＩＭＢ４１１８１、又は緑膿菌（P. aeruginosa）を標的とする能力を保持するこれらの変異株から選択されるバクテリオファージ。   Targets the bacteriophage strains NCIMB41174, NCIMB41175, NCIMB41176, NCIMB41177, NCIMB41178, NCIMB41179, NCIMB41180 and NCIMB41181, or P. aeruginosa, deposited in the National Collection of Industrial and Marine Bacteria, Aberdeen, UK A bacteriophage selected from these mutant strains. 請求項１５記載の１若しくはそれ以上のバクテリオファージを製薬用担体又は希釈剤と共に含む、医薬組成物。   16. A pharmaceutical composition comprising one or more bacteriophages according to claim 15 together with a pharmaceutical carrier or diluent. 緑膿菌（Pseudomonas aeruginosa）を含むか又はそれからなる細菌感染症を処置する目的で、バクテリオファージの集団を同時、別個、又は連続投与するための複合製品であって、該集団の各メンバーはそれぞれ異なる株特異性を有し、且つ該集団が、ＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８、ＮＣＩＭＢ４１１７９、ＮＣＩＭＢ４１１８０、ＮＣＩＭＢ４１１８１及び緑膿菌を標的とする能力を保持するこれらの変異株から選択される２若しくはそれ以上のバクテリオファージからなる、上記複合製品。   A combined product for the simultaneous, separate or sequential administration of a bacteriophage population for the purpose of treating a bacterial infection comprising or consisting of Pseudomonas aeruginosa, each member of the population 2 or selected from these strains having different strain specificity and wherein the population retains the ability to target NCIMB41174, NCIMB41175, NCIMB41176, NCIMB41177, NCIMB41178, NCIMB41179, NCIMB41180, NCIMB41181 and Pseudomonas aeruginosa The above complex product consisting of more bacteriophages. 前記バクテリオファージの集団が、バクテリオファージＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８、ＮＣＩＭＢ４１１７９よりなるか、又は前記のバクテリオファージのいずれかが所望の標的株特異性を示すその変異株に置換されている点で前記集団とは異なる集団である、請求項１７記載の複合製品。   The bacteriophage population consists of bacteriophages NCIMB41174, NCIMB41175, NCIMB41176, NCIMB41177, NCIMB41178, NCIMB41179, or any of the bacteriophages has been replaced with a mutant exhibiting the desired target strain specificity 18. The composite product of claim 17, wherein the product is a group different from the group. 前記バクテリオファージの集団を製薬用担体又は希釈剤と共に含む単一の医薬組成物である、請求項１７又は１８記載の複合製品。   19. A complex product according to claim 17 or 18, which is a single pharmaceutical composition comprising the population of bacteriophages together with a pharmaceutical carrier or diluent. １若しくはそれ以上のバクテリオファージに対して、同時、別個、又は連続投与するための１若しくはそれ以上の抗生物質を更に含む、請求項１６〜１９のいずれか１項に記載の組成物又は複合製品。   20. A composition or complex product according to any one of claims 16 to 19, further comprising one or more antibiotics for simultaneous, separate or sequential administration to one or more bacteriophages. . １若しくはそれ以上のバクテリオファージに対して、同時、別個、又は連続投与するためのアルギナーゼを更に含む、請求項１６〜２０のいずれか１項に記載の組成物又は複合製品。   21. A composition or composite product according to any one of claims 16 to 20, further comprising arginase for simultaneous, separate or sequential administration to one or more bacteriophages. 緑膿菌（P. aeruginosa）を含むか又はそれからなる細菌感染症を処置するための医薬の製造における、請求項１６〜２１のいずれか１項に記載の組成物又は複合製品の使用。   Use of a composition or composite product according to any one of claims 16 to 21 in the manufacture of a medicament for treating a bacterial infection comprising or consisting of P. aeruginosa. 前記感染症が、皮膚熱傷部若しくは他の皮膚創傷部の感染症、肺感染症、眼感染症又は耳感染症から選択される感染症である、請求項２２記載の使用。   23. Use according to claim 22, wherein the infection is an infection selected from infections of skin burns or other skin wounds, lung infections, eye infections or ear infections. 前記感染症がイヌの耳感染症である、請求項２３記載の使用。   24. Use according to claim 23, wherein the infection is a canine ear infection. 前記医薬が予防的処置のために用いられる、請求項２２記載の使用。   23. Use according to claim 22, wherein the medicament is used for prophylactic treatment. 生物膜形成を特徴とする細菌汚染を排除、軽減、又は防止する非治療的方法であって、該汚染の細菌を標的とすることが可能な１若しくはそれ以上のバクテリオファージ及びそれと同時、別個、又は連続に１若しくはそれ以上の抗生物質又は消毒剤を、該汚染部位又はその予測部位に適用することを含む、上記方法。   A non-therapeutic method of eliminating, mitigating or preventing bacterial contamination characterized by biofilm formation, wherein one or more bacteriophages capable of targeting the contaminating bacteria and simultaneously, separately; Or continuously applying one or more antibiotics or disinfectants to the site of contamination or its predicted site. 請求項１０〜１２のいずれか１項に規定される１若しくはそれ以上のバクテリオファージを用いる、請求項２６記載の方法。   27. A method according to claim 26, wherein one or more bacteriophages as defined in any one of claims 10-12 are used. 緑膿菌（P. aeruginosa）を含むか又はそれからなる細菌汚染を排除、軽減、又は防止する非治療的方法であって、請求項１０〜１２のいずれか１項に規定される１若しくはそれ以上のバクテリオファージを該汚染部位又はその予測部位に適用することを含む、上記方法。   13. A non-therapeutic method for eliminating, reducing or preventing bacterial contamination comprising or consisting of P. aeruginosa, comprising one or more as defined in any one of claims 10-12 Applying said bacteriophage to said contaminated site or predicted site thereof. ｉｎ ｖｉｔｒｏサンプル中の緑膿菌（P. aeruginosa）の存在を検出する方法であって、該サンプルを請求項１０〜１２のいずれか１項に規定される１若しくはそれ以上のバクテリオファージと接触させ、そして該バクテリオファージがサンプル中の細菌を死滅させることが可能かどうか決定することを含む、上記方法。   A method for detecting the presence of P. aeruginosa in an in vitro sample, wherein the sample is contacted with one or more bacteriophages as defined in any one of claims 10-12. And determining whether the bacteriophage is capable of killing bacteria in the sample. バクテリオファージＮＣＩＭＢ４１１７４、ＮＣＩＭＢ４１１７５、ＮＣＩＭＢ４１１７６、ＮＣＩＭＢ４１１７７、ＮＣＩＭＢ４１１７８、ＮＣＩＭＢ４１１７９、ＮＣＩＭＢ４１１８０及びＮＣＩＭＢ４１１８１のうち１種類に対して選択的な細菌株を特定する方法であって、いくつかの細菌株での該バクテリオファージによるプラーク形成を測定するステップ、及び前記の他のバクテリオファージよりも該バクテリオファージによって少なくとも１０００倍多くのプラーク形成がなされる株を選択するステップを含む、上記方法。   Bacteriophage NCIMB41174, NCIMB41175, NCIMB41176, NCIMB41177, NCIMB41178, NCIMB41179, NCIMB41180 and NCIMB41181, a method for identifying a bacterial strain selective for one of the bacterial strains, and plaque formation by the bacteriophage in several bacterial strains And selecting a strain that produces at least 1000 times more plaque formation by said bacteriophage than said other bacteriophage. 請求項３０記載の方法により特定される細菌株。   A bacterial strain identified by the method of claim 30. 治療用途を意図する調製物中に存在するバクテリオファージを特定及び／若しくは定量するため、並びに／又は該治療用途中若しくはその後に取得した組織サンプル中に存在する株を特定するための、請求項３１記載の１若しくはそれ以上の細菌株の使用。 32. To identify and / or quantify bacteriophages present in a preparation intended for therapeutic use and / or to identify strains present in tissue samples obtained during or after said therapeutic use. Use of one or more bacterial strains as described.
JP2006520908A 2003-07-23 2004-07-23 Bacteriophage-containing therapeutics Expired - Lifetime JP5731727B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0317240.0 2003-07-23
GB0317240A GB0317240D0 (en) 2003-07-23 2003-07-23 Therapeutic agents
GB0410855A GB0410855D0 (en) 2004-05-14 2004-05-14 Therapeutic agents
GB0410855.1 2004-05-14
PCT/GB2004/003237 WO2005009451A1 (en) 2003-07-23 2004-07-23 Bacteriophage-containing therapeutic agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012242956A Division JP5856556B2 (en) 2003-07-23 2012-11-02 Bacteriophage-containing therapeutics

Publications (3)

Publication Number Publication Date
JP2006528166A JP2006528166A (en) 2006-12-14
JP2006528166A5 true JP2006528166A5 (en) 2007-08-09
JP5731727B2 JP5731727B2 (en) 2015-06-10

Family

ID=34105984

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006520908A Expired - Lifetime JP5731727B2 (en) 2003-07-23 2004-07-23 Bacteriophage-containing therapeutics
JP2012242956A Expired - Lifetime JP5856556B2 (en) 2003-07-23 2012-11-02 Bacteriophage-containing therapeutics

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012242956A Expired - Lifetime JP5856556B2 (en) 2003-07-23 2012-11-02 Bacteriophage-containing therapeutics

Country Status (7)

Country Link
US (5) US7807149B2 (en)
EP (2) EP2570130B1 (en)
JP (2) JP5731727B2 (en)
AU (1) AU2004258731B2 (en)
CA (1) CA2533352C (en)
ES (2) ES2556243T3 (en)
WO (1) WO2005009451A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807149B2 (en) 2003-07-23 2010-10-05 Biocontrol Limited Bacteriophage-containing therapeutic agents
JP2008535480A (en) * 2005-03-04 2008-09-04 ブレイズ ベンチャー テクノロジーズ リミテッド Bacteria collection method and collection apparatus
CN100363489C (en) * 2005-06-16 2008-01-23 华中科技大学同济医学院附属同济医院 Imipenem-resistant pseudomonas aeruginosa bacteriophage and application thereof in treating infection of imipenem-resistant pseudomonas aeruginosa
CA2614800C (en) 2005-07-12 2018-10-30 The University Of Leeds Bacteriophage specifically for lysing propionibacterium acnes and uses thereof
EP2004800B1 (en) 2006-04-04 2014-01-15 Henry Morris Krisch Process of production of bacteriophage compositions and methods in phage therapy field
GB0704553D0 (en) * 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments
WO2009076668A2 (en) * 2007-12-13 2009-06-18 Alpharma, Inc. Bacteriophage preparations and method of use thereof
US9320795B2 (en) * 2007-12-13 2016-04-26 Zoctis Server LLC Bacteriophage preparations and methods of use thereof
KR20100093626A (en) * 2009-02-17 2010-08-26 서강대학교산학협력단 Phage therapy against pseudomonas aeruginosa
WO2010141135A2 (en) 2009-03-05 2010-12-09 Trustees Of Boston University Bacteriophages expressing antimicrobial peptides and uses thereof
TW201130980A (en) * 2010-03-02 2011-09-16 Univ Ishou A new lytic phage specific to Klebsiella pneumoniae
CA2837731C (en) 2011-06-28 2018-05-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Controlled covalent attachment of bioactive bacteriophage for regulating biofilm development
US12083158B2 (en) 2011-10-07 2024-09-10 Morehouse School Of Medicine Antibacterial compositions, methods of making and use thereof
US8669226B2 (en) 2011-10-07 2014-03-11 Morehouse School Of Medicine Antimicrobial compositions and methods of use thereof
WO2013164640A1 (en) * 2012-05-04 2013-11-07 Biocontrol Limited Therapeutic bacteriophage compositions
DE102013106455A1 (en) 2013-06-20 2014-12-24 Airbus Defence and Space GmbH Method for decontamination of bacteriological contaminants
PL405911A1 (en) 2013-11-04 2015-05-11 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Protein with hydrolytic activity towards polysaccharide bacterial capsules, the polynucleotide coding that protein, biologically active vector, composition containing the protein and its applications
US11058131B2 (en) 2015-04-16 2021-07-13 Kennesaw State University Research And Service Foundation, Inc. Escherichia coli O157:H7 bacteriophage Φ241
US10517908B2 (en) 2015-08-13 2019-12-31 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions
PT3440200T (en) * 2016-04-08 2021-04-30 Phico Therapeutics Ltd Modified bacteriophage
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2017189518A1 (en) * 2016-04-25 2017-11-02 Yale University Bacteriophage compositions and uses thereof
JP7370867B2 (en) 2017-02-13 2023-10-30 アルマタ・ファーマシューティカルズ・インコーポレーテッド therapeutic bacteriophage composition
CN109837251B (en) * 2017-11-27 2022-01-28 菲吉乐科(南京)生物科技有限公司 Phage protective agent and preparation method and application thereof
CA3087338A1 (en) 2018-01-02 2019-07-11 Armata Pharmaceuticals, Inc. Therapeutic bacteriophage compositions for treating staphylococcus infection
CN112203638A (en) 2018-01-02 2021-01-08 阿玛塔制药股份有限公司 Bacteriophage compositions for treatment of pseudomonas infection
CN108300723B (en) * 2018-01-17 2022-04-08 天津科技大学 Reporter gene system applied to screening of biofilm inhibitor
EP4417710A2 (en) 2018-02-07 2024-08-21 Armata Pharmaceuticals, Inc. Bacteriophage for treatment and prevention of bacteria-associated cancers
EP3801029B1 (en) 2018-05-30 2024-07-10 Morehouse School of Medicine Antibacterial compositions, methods of making and use thereof
CN114844614A (en) * 2019-08-02 2022-08-02 华为技术有限公司 Method for improving measurement capability of terminal equipment, chip and terminal equipment
US12016892B2 (en) * 2021-04-09 2024-06-25 University of Pittsburgh the Commonwealth System of Higher Education Bacteriophages for treatment of tuberculosis

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678750A (en) 1984-10-18 1987-07-07 Microlife Technics, Inc. Method and compositions for use in the treatment of fireblight
US4828999A (en) 1986-07-21 1989-05-09 Jackson Le Roy E Bacteriophage prevention and control of harmful plant bacteria
SU1472500A1 (en) * 1987-07-28 1989-04-15 Тбилисский Научно-Исследовательский Институт Вакцин И Сывороток Strain of pseudomonas aeruginosa bacteriophage used for identifying and indicating pseudomonas aeruginosa microbes
US5032574A (en) 1988-05-26 1991-07-16 Invitron Corporation Novel antimicrobial peptide
US5242902A (en) 1989-09-06 1993-09-07 The Regents Of The University Of California Defensin peptide compositions and methods for their use
JPH07507213A (en) 1992-05-22 1995-08-10 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Digestive defensins, their cDNA sequences and production methods, and their uses
WO1994019006A1 (en) 1993-02-24 1994-09-01 Gunze Limited Remedy for cystic fibrosis
US5459235A (en) 1993-03-19 1995-10-17 The Regents Of The University Of California Antimicrobial peptides antibodies and nucleic acid molecules from bovine neutrophils
US5550109A (en) 1994-05-24 1996-08-27 Magainin Pharmaceuticals Inc. Inducible defensin peptide from mammalian epithelia
WO1997039111A1 (en) 1996-04-15 1997-10-23 Nymox Corporation Compositions containing bacteriophages and methods of using bacteriophages to treat infections
WO1998047521A1 (en) 1997-04-24 1998-10-29 Idaho Research Foundation, Inc. Phages, methods for growing and detecting them and their use
US20020037260A1 (en) 1997-10-16 2002-03-28 Budny John A. Compositions for treating biofilm
EP0925756B8 (en) 1997-12-25 2008-08-13 Nihon Kohden Corporation Biological signal transmission apparatus
US6861230B1 (en) 1998-01-21 2005-03-01 The Secretary Of State For Defence In Her Britannic Majesty's Government Of The United Kingdom Of Great Britain And Northern Ireland Antibiotic sensitivity testing
US20040208853A1 (en) * 2000-01-11 2004-10-21 Intralytix, Inc. Method and device for sanitation using bacteriophages
US6699701B1 (en) 2000-01-11 2004-03-02 Intralytix, Inc. Method and device for sanitation using bacteriophages
US20020001590A1 (en) 2000-04-20 2002-01-03 Mount Sinai Hospital Antibacterial therapy for multi-drug resistant bacteria
US6485902B2 (en) 2000-06-06 2002-11-26 Thomas E. Waddell Use of bacteriophages for control of escherichia coli O157
DE60113851T2 (en) * 2000-07-25 2006-07-20 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services BAKTERIOPHAGE WITH A WIDE HOMEPAGE
US6461608B1 (en) 2000-11-22 2002-10-08 Nymox Pharmaceutical Corporation Bacteriophage composition useful in treating food products to prevent bacterial contamination
RU2186574C1 (en) 2001-01-24 2002-08-10 Яфаев Рауэль Хасанянович Preparation of polyvalent bacteriophage against pyocyanic bacillus, strains of bacteriphagum pseudomonas aeruginosa used in preparing polyvalent preparation against pyocyanic bacillus
CN1260353C (en) * 2001-07-18 2006-06-21 波兰科学院免疫和实验治疗研究所 Methods of polyvalent bacteriophage prepn. for treatment of bacterial infections
GB0300597D0 (en) 2003-01-10 2003-02-12 Microbiological Res Authority Phage biofilms
US6804620B1 (en) 2003-03-21 2004-10-12 Advantest Corporation Calibration method for system performance validation of automatic test equipment
US7807149B2 (en) 2003-07-23 2010-10-05 Biocontrol Limited Bacteriophage-containing therapeutic agents
US20050051420A1 (en) 2003-09-05 2005-03-10 Sharper Image Corporation Electro-kinetic air transporter and conditioner devices with insulated driver electrodes
GB0704553D0 (en) 2007-03-09 2007-04-18 Harper David R Beneficial effects of bacteriophage treatments

Similar Documents

Publication Publication Date Title
JP2006528166A5 (en)
US11957724B2 (en) Phage therapy of E coli infections
US11779617B2 (en) Phage therapy
JP5856556B2 (en) Bacteriophage-containing therapeutics
CA2928540C (en) Phage therapy of pseudomonas infections
KR101174809B1 (en) A bacteriophage killing Staphylococcus aureus
JP2010521428A5 (en)
Ijaz et al. Frequency of multi drug resistant Pseudomonas aeruginosa in different wound types of hospitalized patients.
Rezk et al. Bacteriophage as a potential therapy to control antibiotic-resistant Pseudomonas aeruginosa infection through topical application onto a full-thickness wound in a rat model
El-Gayar et al. Antivirulence and wound healing effects of royal jelly and garlic extract for the control of MRSA skin infections
Naqvi et al. Multidrug resistant Pseudomonas aeruginosa: a nosocomial infection threat in burn patients
Cooper et al. Testing the susceptibility to manuka honey of streptococci isolated from wound swabs
Ryssel et al. Antiseptic therapy with a polylacticacid–acetic acid matrix in burns
Shree et al. Effect of Klebsiella-specific phage on multidrug-resistant Klebsiella pneumoniae-an experimental study
Guliy et al. The role of biofilms and multidrug resistance in wound infections
da Silva In vitro evaluation of an antibiofilm product: a combination between bacteriophages and Portuguese honey
Hernandez-Romero et al. Rifampicin and N-acteylcisteyne inhibit oral bacterial growth and biofilm formation
Pallavali et al. Lytic Bacteriophages and Phage Cocktails Seem to be a Future Alternative Against Multi-Drug Resistant Bacterial Infections
Gwynne Developing a Theranostic Device for the Treatment of Staphylococcus Aureus Infections
Mokhtar Modulating the susceptibilities of bacteria to antibiotics using Manuka honey
Fatima et al. Temperate phages increase antibiotic effectiveness in a Caenorhabditis elegans infection model
KR20220099102A (en) Anti-microorganism composition comprising pseudomona `s aeruginosa culture or its extract and uses thereof
Isaac et al. Teat-apex colonizer Bacillus from healthy cows antagonizes mastitis-causing Staphylococcus aureus biofilms
Ehsanollah et al. Anti-adhesive and anti-invasive activities of an oil based di-herbal extract against methicillin resistant Staphylococcus aureus